BeyondSpring competitorsClear all

BeyondSpring's top competitors include Omeros, Athersys, Otonomy and Mirati Therapeutics.
BeyondSpring
BeyondSpring
BeyondSpring (also known as Spring Pharmaceuticals) is a biopharmaceutical company.
Omeros
Omeros
Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.
Athersys
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Otonomy
Otonomy
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
Mirati Therapeutics
Mirati Therapeutics
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs.
Founding Date
Founding Date
2010
Founding Date
1994
Founding Date
1995
Founding Date
2008
Founding Date
2013
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
New York, US HQ
Locations
Seattle, US HQ
Locations
Cleveland, US HQ
Canton, US
Locations
San Diego, US HQ
Locations
San Diego, US HQ
Employees
Employees
6117% increase
Employees
2589% increase
Employees
8311% increase
Employees
49
Employees
11176% increase
Valuation ($)
Valuation ($)
502.6 m
Valuation ($)
1.1 b
Valuation ($)
361.8 m
Valuation ($)
123.7 m
Valuation ($)
9.7 b
Twitter followers
Twitter followers
118
Twitter followers
292
Twitter followers
2.2 k
Twitter followers
214
Twitter followers
349
Number of tweets (last 30 days)
Number of tweets (last 30 days)
10
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
8
Number of tweets (last 30 days)
N/A
Number of tweets (last 30 days)
N/A
Average likes per tweet (last 30 days)
Average likes per tweet (last 30 days)
0.5
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
15.9
Average likes per tweet (last 30 days)
N/A
Average likes per tweet (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
Percentage of tweets with engagement (last 30 days)
60%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
100%
Percentage of tweets with engagement (last 30 days)
N/A
Percentage of tweets with engagement (last 30 days)
N/A
Alexa Website Rank
Alexa Website Rank
277952
Alexa Website Rank
200197
Alexa Website Rank
269719
Alexa Website Rank
274621
Alexa Website Rank
268626
Employee Rating
Employee Rating
2.6
Employee Rating
3.2
Employee Rating
4
Employee Rating
4.3
Employee Rating
N/A

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$73.8m (FY, 2020)
Revenue (est.)
$5.6m (FY, 2019)
Revenue (est.)
$273k (FY, 2020)
Revenue (est.)
$13.4m (FY, 2020)
Cost of goods
Cost of goods
N/A
Cost of goods
$902k (FY, 2020)
Cost of goods
N/A
Cost of goods
$1.2m (FY, 2020)
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$72.9m (FY, 2020)
Gross profit
N/A
Gross profit
($915k) (FY, 2020)
Gross profit
N/A
Net income
Net income
($40.3m) (FY, 2019)
Net income
($138.1m) (FY, 2020)
Net income
($44.6m) (FY, 2019)
Net income
($44.7m) (FY, 2020)
Net income
($357.9m) (FY, 2020)

Operating

Patents (US)
Patents (US)
20 (Mar, 2020)
Patents (US)
492 (FY, 2016)
Patents (US)
21 (FY, 2016)
Patents (US)
N/A
Patents (US)
N/A
Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
200 (FY, 2016)
Patents Issued
88 (FY, 2016)
Patents Issued
32 (FY, 2016)
Patents Pending
Patents Pending
N/A
Patents Pending
N/A
Patents Pending
N/A
Patents Pending
115 (FY, 2016)
Patents Pending
1 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
2 (FY, 2019)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2016)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
2 (FY, 2016)
Phase II Trials Products
N/A
Phase III Trials Products
Phase III Trials Products
3 (FY, 2019)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
2 (FY, 2016)
Phase III Trials Products
N/A
Pre-Clinical Phase Products
Pre-Clinical Phase Products
5 (FY, 2019)
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
N/A
Pre-Clinical Phase Products
1 (FY, 2016)
Pre-Clinical Phase Products
N/A

Funding

Total funding raised
Total funding raised
$ 36.1m
Total funding raised
$ 354.8m
Total funding raised
$ 9m
Total funding raised
$ 153.4m
Total funding raised
N/A
For sources of this data, please see the company profile

View company profiles

Omeros
HQ
Seattle, US
Employees
258↑ 9% increase

Omeros Corporation is a clinical-stage biopharmaceutical company developing products focused on inflammation and central nervous system disorders.

View company
Athersys
HQ
Cleveland, US
Employees
83↑ 11% increase

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company
Otonomy
HQ
San Diego, US
Employees
49

Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.

View company
Mirati Therapeutics
HQ
San Diego, US
Employees
111

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs.

View company